glp-1 pharma companies Europe Agonist Market 'We still believe they're the

A gastric gavage with 150 mg glucose increased circulating levels of glucose and insulin and 8 week pretreatment with NVP DPP728 reduced the increase in glucose and augmented the increase in insulin ( Figure 2 First Clinical Study The first clinical study with a DPP-4 inhibitor was performed with NVP DPP728 at five centers in Sweden and involved 93 patients with mild drug-naive type 2 diabetes (61 men and 32 women)

In a six-month study, Noom members lost 39% more weight than those taking GLP-1 medications alone

(1996) 271:E8216

These adverse effects include nausea, vomiting, anaphylactoid reactions, bronchospasm, hypotension (Ershad et al

doi:10.1002/dta.1402